Lysosomal Enzyme Global Market Report 2025

The lysosomal enzymes market size has grown strongly in recent years. It will grow from $9.47 billion in 2024 to $10.07 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth during the historic period can be attributed to the increasing prevalence of lysosomal storage disorders, improved awareness and diagnosis rates, rising investments in rare disease research, favorable regulatory support, advancements in biotechnology, and enhanced access to orphan drugs.

The lysosomal enzymes market size is expected to see strong growth in the next few years. It will grow to $12.73 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The projected growth during the forecast period can be attributed to increased investments in rare disease research, the rise of gene therapy, the expansion of newborn screening programs, growing adoption of enzyme replacement therapies, emerging innovations in biopharmaceuticals, and supportive regulatory frameworks for orphan drugs. Key trends expected in this period include the integration of gene therapy, advancements in enzyme replacement treatments, development of targeted drug delivery systems, biomarker-based diagnostic methods, personalized therapeutic approaches, improved techniques for crossing the blood-brain barrier, and broadened therapeutic applications.

The rising adoption of gene therapy is expected to drive the growth of the lysosomal enzymes market in the coming years. Gene therapy is a medical approach that involves modifying or replacing genes within a patient’s cells to treat or prevent disease. Its adoption is growing due to advancements in delivery vectors and proven long-term effectiveness, making it a viable and potentially curative solution for genetic disorders. Gene therapy often necessitates initial or complementary enzyme replacement therapy to manage symptoms and stabilize patients while the gene therapy becomes effective, thereby maintaining the demand for lysosomal enzyme products. For example, in April 2024, the American Society of Gene & Cell Therapy, a US-based non-profit organization, reported that the number of phase III gene therapy clinical trials increased by 10% in 2023, representing the first quarterly growth since 2022. As a result, the growing use of gene therapy is expected to support the expansion of the lysosomal enzymes market.

Leading companies in the lysosomal enzymes market are prioritizing strategic partnerships to enhance diagnostic capabilities and accelerate the development of innovative therapies. Strategic partnerships involve collaborative agreements between organizations that pool resources or expertise to achieve shared objectives and strengthen their competitive positioning. For example, in February 2024, a biotechnology company based in Spain entered into a partnership with Biosidus, an Argentina-based biotechnology firm, to produce the active enzyme ingredient Agalsidase Beta. This partnership represents a significant step forward in the development and production of treatments for rare diseases, particularly Fabry disease, which is caused by a lysosomal enzyme deficiency. It also marks a regional milestone in rare disease care and underscores the companies’ dedication to advancing global health and promoting accessible biopharmaceutical innovation.

In March 2024, CENTOGENE, a biotechnology research company based in Germany, formed a partnership with Takeda Pharmaceutical Company Limited. This collaboration aims to enhance global access to fast and accurate diagnostics for rare lysosomal diseases, thereby supporting earlier detection and improved treatment outcomes, particularly in underserved populations. Takeda Pharmaceutical Company Limited is a Japan-based supplier of lysosomal enzymes.

Major players in the lysosomal enzyme market are Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, BioMarin Pharmaceutical Inc., Amicus Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Sangamo Therapeutics Inc., Protalix BioTherapeutics Inc., Orchard Therapeutics Plc, Alexion Pharmaceuticals Inc., ISU Abxis Co. Ltd., Chiesi Farmaceutici S.p.A., GC Pharma Co. Ltd., Genzyme Corp., Shire plc, Greenovation Biotech GmbH, Oxyrane, Avrobio Inc., Ultragenyx Pharmaceutical Inc.

North America was the largest region in the lysosomal enzymes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lysosomal enzymes report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lysosomal enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lysosomal enzymes are specialized hydrolytic enzymes located within lysosomes, which are membrane-bound organelles present in eukaryotic cells. These enzymes are essential for cellular digestion, as they break down a variety of biological macromolecules such as proteins, lipids, carbohydrates, and nucleic acids. A deficiency or dysfunction in these enzymes can result in serious genetic conditions known as lysosomal storage diseases, where undigested substances accumulate inside cells and impair their normal function.

The primary types of lysosomal enzymes include acid alpha-glucosidase, acid sphingomyelinase, beta-glucocerebrosidase, and hexosaminidase. Acid alpha-glucosidase functions to degrade glycogen into glucose within the lysosome. These enzymes are used to treat multiple disorders such as Gaucher disease, mucopolysaccharidosis, Pompe disease, and others. They are sourced from recombinant, natural, and synthetic origins and are applied in areas such as enzyme replacement therapy, research and development, diagnostics, and gene therapy. Their usage spans various environments including hospitals, diagnostic labs, research centers, and pharmaceutical companies.

The lysosomal enzyme market research report is one of a series of new reports that provides lysosomal enzyme market statistics, including the lysosomal enzyme industry global market size, regional shares, competitors with the lysosomal enzyme market share, detailed lysosomal enzyme market segments, market trends, and opportunities, and any further data you may need to thrive in the lysosomal enzyme industry. This lysosomal enzyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lysosomal enzymes market consists of sales of small molecule drugs, diagnostic kits, nutritional supplements, infusion kits, and accessories. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.